Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access
NCT07858331 on ClinicalTrials.gov · last registry update 2026-10-05
An unusually large phase 4: 880 participants, more than double the 75 typical for the stage. Due to report 1 January 2029, alongside 11 other tracked readouts that quarter. Primary outcome, as filed: Change in Body Weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for chronic kidney disease and obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Kristin Clemens
- Sponsor type
- Other
- Enrollment
- 880
- Started
- 2027-01-01
- Primary completion
- 2029-01-01 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-10-05 | First seen in registry | Registered as NOT_YET_RECRUITING, P4 |
Primary outcome
Change in Body Weight
Conditions studied
Obesity · Chronic Kidney Disease · Chronic Renal Disease · CKD
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.